MarginsXMarginsX
Home › Markets › Health Care › EDSA

Edesa Biotech Inc. Common Shares (EDSA)

EDSA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.89
-2.58% on the day
Market cap
$25.5M
Nano cap
Revenue · 2021
$0
-100.0% on 2020
Net income · 2021
-$13.3M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2021-09-30, https://www.sec.gov/Archives/edgar/data/1540159/000165495421013551/0001654954-21-013551-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2021-09-30.

Profile

FieldValue
TickerEDSA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001540159
SEC industry codePharmaceutical Preparations
Incorporated inBC

Financials · 2021

LineValue
Revenue$0
Net income-$13.3M
Operating income-$23.7M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$7.8M
Total assets$14.6M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
13.9 months
$10.3M cash at June 30, 2026
Share count, 1 year
+37.0%
2025-08-08 to 2026-08-13 · +219.9% over 3 years
Going-concern doubt
No
10-Q filed August 13, 2026
Insider net buying, 12 months
$233K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"These conditions indicate the existence of a material uncertainty that may cast substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-08-13
Cash and burn$10.3M cash; operating cash flow -$2.2M a quarter.Report 2026-06-30
Shares outstanding9,641,031 (2026-08-13); 7,037,648 a year earlier; 21,093,654 three years earlier. 3y figure adjusted for splits (1-for-7 overall).Cover page 2026-08-13
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-08-20
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorMNP LLP, Toronto, CanadaPCAOB Form AP 2025-12-15
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $233K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-06-30
Not filed-$5.4M-$3.1M$10.3MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q2 2026
2026-03-31
Not filed-$4.2M-$2.0M$10.0MNo debt tagsNeeds four quarters10-Q 2026-05-14
Q1 2026
2025-12-31
Not filed-$2.2M-$2.1M$12.1MNo debt tagsNeeds four quarters10-Q 2026-02-13
Q4 2025
2025-09-30
Not filed-$2.2M-$1.7M$10.8MNo debt tagsNeeds four quarters10-K 2025-12-12
Q3 2025
2025-06-30
Not filed-$1.7M-$1.7M$12.4MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q2 2025
2025-03-31
Not filed-$1.6M-$2.4M$13.9MNo debt tagsNeeds four quarters10-Q 2026-05-14
Q1 2025
2024-12-31
Not filed-$1.6M-$1.5M$1.6MNo debt tagsNeeds four quarters10-Q 2026-02-13
Q4 2024
2024-09-30
Not filed-$962K-$967K$1.0MNo debt tagsNeeds four quarters10-K 2025-12-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-08-20
Latest annual report
FORM 10-K
10-K2025-12-12
Latest quarterly / interim
FORM 10-Q
10-Q2026-08-13
Latest current report
FORM 8-K
8-K2026-11-09
Latest proxyDEFA14A2026-04-03

Source: SEC EDGAR submissions feed, 758 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-9.3%
1 month-31.9%
3 months-64.3%
Year to date+36.6%
1 year+12.1%
From 52-week high-89.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
LITSLite Strategy Inc.$0.8565+1.16%$25.6M
ABVCABVC BioPharma Inc.$0.9400+3.30%$25.4M
ACETAdicet Bio Inc.$2.75-1.08%$25.7M
CRVOCervoMed Inc.$1.67-1.18%$25.3M
IMMPImmutep Limited$3.40-2.30%$25.1M
MIRAMIRA Pharmaceuticals Inc.$0.6310-4.38%$26.5M
RMTIRockwell Medical Inc.$6.76-4.38%$26.9M
IXHLIncannex Healthcare Inc.$1.93-2.03%$24.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier